Company: STAA
Filing Date: 2025-11-04
Form Type: DFAN14A
Source: 0001104659-25-105834
Chunk: 11

Company: STAAR SURGICAL CO
Filing Date: 2025-11-04
Form: DFAN14A
Chunk 11
---
02/you - cant - cost - cut - your - way - t o - growth/ 2. STAAR Q2 2025 Earnings Call, August 2025 23.6 2Q24 21.0 2Q25 G&A - 11% 11.9 2Q24 10.3 2Q25 R&D - 13% Q2 2025 expense 2 $m "You Can’t Cost Cut Your Way To Growth 1 ” “Q2 year - over - year decrease is due to lower marketing, promotional and advertising activities …” 2 31.0 2Q24 26.3 2Q25 S&M - 15%

13 STAAR’s Q3’25 performance does not provide any indication that a corner is being turned 1 89 69 Net Sales - 22% Q3’24 Q3’25 STAAR Q3 YoY Financial Performance , $m 1 1. Q3’25 results exclude revenue associated with the previously disclosed Dec 2024 ICL shipment that was recognized Q3’25 2. STAAR Management Presentation: Alcon Merger Maximizes Value for Stockholders of STAAR Surgical – September 2025 • Q3 represents the first quarter that is mostly clear of China inventory issues • Excluding ICL shipment from Dec 2024 that was recognized in Q3, revenue is down double digits year - over - year in Q3 • STAAR believes China procedural volumes for EVO ICLs are essentially flat year to date – positive year over year in Q1’25, softened during Q2’25, and have not improved so far in Q3’25 2 • STAAR does not expect to be profitable FY’25 despite aggressive cost savings initiatives implemented to align STAAR’s cost structure with sales 2 Excludes $25.9m in Q4 ’24 revenue recognized in Q3 ‘25

14 Current valuation reflects reality Activist stockholders a re engineering a silent takeover Merger is best option for stockholders

15 Activist stockholders are engineering a silent takeover of STAAR without paying any premium 1 1. Alcon estimates 2. S&P CapitalIQ : Broadwood Capital, Inc.| Activist Profile 3. As shown in Schedule 13D filed with the SEC on September 22, 2025 4. As shown in Schedule 13D/A filed with the SEC on November 3,